Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective

por Dunlop, Will, van Keep, Marjolijn, Elroy, Peter, Perez, Ignacio Diaz, Ouwens, Mario J. N. M., Sarbajna, Tina, Zhang, Yiduo, Greystoke, Alastair
Publicado 2021